Lisa Maurer, MD, PhD

Summary

My research focuses on studying the protein-protein interactions within the “CBM” signaling complex, composed of CARMA1 (a scaffolding protein), BCL10 (an adaptor protein), and MALT1 (a scaffolding protein with proteolytic activity). In normal lymphocytes, the CBM complex mediates activation of the pro-survival NF-kappaB transcription factor in response to antigen receptor stimulation. Inappropriate activation of this complex drives neoplastic diseases including lymphoid cancers such as non-Hodgkin Lymphoma and likely a subset of pediatric T-cell lymphoma. My goal is to understand how inhibiting protein-protein interactions within this complex alters the pathogenesis of these malignancies and to determine if inhibiting protein-protein interactions within the CBM complex represents a novel treatment strategy for a subset of patients with lymphoma.